Here are the staff publications for December 2017 and January 2018, compiled 31st January 2018.

Here are the staff publications for December 2017 and January 2018.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 31st January 2018.

1. Abbott SC, Stevenson ARL, Bell SW, Clark D, Merrie A, Hayes J, Ganesh S, Heriot AG, Warrier SK. An assessment of an Australasian pathway for the introduction of transanal total mesorectal excision (taTME). Colorectal Disease 2018;20:O1-O6.

2. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Cordonnier C, Maertens J, Bretagne S. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy 2016;71:2386-96.

3. Alexander M, Solomon B, Burbury K. Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. Clinical Lung Cancer 2018;19:e71-e2.

4. Arora S, Abaza R, Adshead JM, Ahlawat RK, Challacombe BJ, Dasgupta P, Gandaglia G, Moon DA, Yuvaraja TB, Capitanio U, Larcher A, Porpiglia F, Porter JR, Mottrie A, Bhandari M, Rogers C. 'Trifecta' outcomes of robot-assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis. BJU International 2018;121:119-23.

5. Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation 2017;127:929-41.

6. Bell CC, Dawson MA. TFIID and MYB Share a Therapeutic Handshake in AML. Cancer Cell 2018;33:1-3.

7. Belobrov S, Cornall AM, Young RJ, Koo K, Angel C, Wiesenfeld D, Rischin D, Garland SM, McCullough M. The role of human papillomavirus in p16-positive oral cancers. Journal of Oral Pathology & Medicine 2018;47:18-24.

8. Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 2018;32:83-91.

9. Busuttil RA, Liu DS, Di Costanzo N, Schroder J, Mitchell C, Boussioutas A. An orthotopic mouse model of gastric cancer invasion and metastasis. Scientific Reports 2018;8:825.

10. Chang CC, Slavin MA, Chen SC. New developments and directions in the clinical application of the echinocandins. Arch Toxicol 2017;91:1613-21.

11. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, Bak N, Heath CH, Kennedy K, Morrissey CO, Sorrell TC, van Hal S, Keighley C, Goeman E, Underwood N, Hajkowicz K, Hofmeyr A, Leung M, Macesic N, Botes J, Blyth C, Cooley L, George CR, Kalukottege P, Kesson A, McMullan B, Baird R, Robson J, Korman TM, Pendle S, Weeks K, Liu E, Cheong E, Chen S. Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy 2017;72:1270.

12. Christidis D, McGrath S, Leaney B, O'Sullivan R, Lawrentschuk N. Interpreting Prostate Multiparametric Magnetic Resonance Imaging: Urologists' Guide Including Prostate Imaging Reporting and Data System. Urology 2018;111:136-8.

13. Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer. Annals of Oncology 2017;28:viii13-viii5.

14. Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. Journal of Clinical Oncology 2017;35:1274-80.

15. Cluse LA, Nikolic I, Knight D, Madhamshettiwar PB, Luu J, Cowley KJ, Semple T, Arnau GM, Shortt J, Johnstone RW, Simpson KJ. A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. Methods in Molecular Biology 2018;1725:201-27.

16. Colombo AL, de Almeida Junior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infectious Diseases 2017;17:e344-e56.

17. Cordonnier C, Alanio A, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Maertens J. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response. Journal of Antimicrobial Chemotherapy 2017;72:1266-8.

18. Cordonnier C, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Maertens J. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy 2016;71:2379-85.

19. Darby WG, Grace MS, Simpson KJ, Woodman OL, McIntyre P. A Functional Kinase Short Interfering Ribonucleic Acid Screen Using Protease-Activated Receptor 2-Dependent Opening of Transient Receptor Potential Vanilloid-4. Assay and Drug Development Technologies 2018;16:15-26.
20. Darido C, Georgy SR, Cullinane C, Partridge DD, Walker R, Srivastava S, Roslan S, Carpinelli MR, Dworkin S, Pearson RB, Jane SM. Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin. Cell Death Differ 2017.

21. Doig KD, Ellul J, Fellowes A, Thompson ER, Ryland G, Blombery P, Papenfuss AT, Fox SB. Canary: an atomic pipeline for clinical amplicon assays. BMC Bioinformatics 2017;18:555.

22. Duarte D, Hawkins ED, Akinduro O, Ang H, De Filippo K, Kong IY, Haltalli M, Ruivo N, Straszkowski L, Vervoort SJ, McLean C, Weber TS, Khorshed R, Pirillo C, Wei A, Ramasamy SK, Kusumbe AP, Duffy K, Adams RH, Purton LE, Carlin LM, Lo Celso C. Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML. Cell Stem Cell 2018;22:64-77 e6.

23. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, Davis BJ. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Practical Radiation Oncology 2018;8:28-39.

24. Fleming M, King C, Rajeev S, Baruwal A, Schwarz D, Schwarz R, Khadka N, Pande S, Khanal S, Acharya B, Benton A, Rogers SO, Panizales M, Gyorki D, McGee H, Shaye D, Maru D. Surgical referral coordination from a first-level hospital: a prospective case study from rural Nepal. BMC Health Services Research 2017;17:676.

25. Forrest L, Mitchell G, Thrupp L, Petelin L, Richardson K, Mascarenhas L, Young MA. Consumer attitudes towards the establishment of a national Australian familial cancer research database by the Inherited Cancer Connect (ICCon) Partnership. Journal of Community Genetics 2018;9:57-64.

26. Guerra GR, Kong JC, Bernardi MP, Ramsay RG, Phillips WA, Warrier SK, Lynch AC, Ngan SY, Heriot AG. Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. Diseases of the Colon and Rectum 2018;61:179-86.

27. Harvey Y, Bleakley S, Blombery P, Bain BJ. Marked leukemoid reaction in a patient with metastatic breast carcinoma. American Journal of Hematology 2018;93:306-7.

28. Hirshoren N, Olayos E, Herschtal A, Ravi Kumar AS, Gyorki DE. Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma. Otolaryngology--Head and Neck Surgery 2018;158:122-6.

29. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018;38:200-17.

30. Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, Hicks RJ. (68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging 2017;17:31.

31. Jeong W, Snell GI, Levvey BJ, Westall GP, Morrissey CO, Ivulich S, Neoh CF, Slavin MA, Kong DCM. Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience. Journal of Antimicrobial Chemotherapy 2017;72:2089-92.

32. Kasivisvanathan V, Ahmed H, Cashman S, Challacombe B, Emberton M, Gao C, Lamb BW, Nambiar A, Pickard R, Shah TT, Smith D. The British Urology Researchers in Surgical Training (BURST) Research Collaborative: an alternative research model for carrying out large scale multi-centre urological studies. BJU International 2018;121:6-9.

33. Keam SP, Caramia F, Gamell C, Paul PJ, Arnau GM, Neeson PJ, Williams SG, Haupt Y. The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort. International Journal of Radiation Oncology, Biology, Physics 2018;100:188-98.

34. Klaassen Z, Murphy DG. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naive prostate cancer: changing the LATITUDE. BJU International 2018;121:9-11.

35. Lamboley CR, Xu H, Dutka TL, Hanson ED, Hayes A, Violet JA, Murphy RM, Lamb GD. Effect of androgen deprivation therapy on the contractile properties of type I and type II skeletal muscle fibres in men with non-metastatic prostate cancer. Clin Exp Pharmacol Physiol 2018;45:146-54.

36. Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. Journal of Clinical Neurosciences 2018;47:168-73.

37. Li N, Rowley SM, Thompson ER, McInerny S, Devereux L, Amarasinghe KC, Zethoven M, Lupat R, Goode D, Li J, Trainer AH, Gorringe KL, James PA, Campbell IG. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs. Breast Cancer Research 2018;20:3.

38. Lim KYB, Godde NJ, Humbert PO, Kvansakul M. Structural basis for the differential interaction of Scribble PDZ domains with the guanine nucleotide exchange factor beta-PIX. Journal of Biological Chemistry 2017;292:20425-36.
39. Lipson-Smith R, Hyatt A, Murray A, Butow P, Hack TF, Jefford M, Ozolins U, Hale S, Schofield P. Measuring recall of medical information in non-English-speaking people with cancer: A methodology. Health Expectations 2018;21:288-99.

40. Luen S, Wong SW, Mar V, Kelly JW, McLean C, McArthur GA, Haydon A. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics. American Journal of Clinical Oncology 2018;41:90-4.

41. Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. Journal of Antimicrobial Chemotherapy 2016;71:2397-404.

42. Marcus R, Seymour JF, Hiddemann W. Obinutuzumab Treatment of Follicular Lymphoma. New England Journal of Medicine 2017;377:2605-6.

43. Marks DI, Liu Q, Slavin M. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. Expert review of anti-infective therapy 2017;15:493-502.

44. Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. Journal of Antimicrobial Chemotherapy 2016;71:2405-13.

45. Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection 2018;76:20-37.

46. Miles LB, Darido C, Kaslin J, Heath JK, Jane SM, Dworkin S. Mis-expression of grainyhead-like transcription factors in zebrafish leads to defects in enveloping layer (EVL) integrity, cellular morphogenesis and axial extension. Scientific Reports 2017;7:17607.

47. Moloczij N, Gough K, Solomon B, Ball D, Mileshkin L, Duffy M, Krishnasamy M. Development of a hospital-based patient-reported outcome framework for lung cancer patients: a study protocol. Health and Quality of Life Outcomes 2018;16:10.

48. Morgan DD, Marston C, Garner J, Currow DC. Subacute Rehabilitation Does Have Benefits for Patients With Advanced Cancer. Journal of Pain and Symptom Management 2018;55:e1-e2.

49. Mossman AK, Pattison DA, Hicks RJ, Hamblin PS, Yates CJ. Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. Internal Medicine Journal 2018;48:97-8.

50. Nikolic I, Elsworth B, Dodson E, Wu SZ, Gould CM, Mestdagh P, Marshall GM, Horvath LG, Simpson KJ, Swarbrick A. Discovering cancer vulnerabilities using high-throughput micro-RNA screening. Nucleic Acids Research 2017;45:12657-70.

51. Nissen MD, Sloan EK, Mattarollo SR. beta-Adrenergic Signaling Impairs Antitumor CD8(+) T-cell Responses to B-cell Lymphoma Immunotherapy. Cancer Immunology Research 2018;6:98-109.

52. Oborn BM, Gargett MA, Causer TJ, Alnaghy SJ, Hardcastle N, Metcalfe PE, Keall PJ. Experimental verification of dose enhancement effects in a lung phantom from inline magnetic fields. Radiotherapy and Oncology 2017;125:433-8.

53. Pascoe C, Manning TG, Wetherell D, Lawrentschuk N. Ureteral intramural metastatic deposit of prostate cancer with ureteric obstruction. BMJ Case Rep 2018;2018.

54. Pass HI, Ball DL, Scagliotti GV. IASLC Thoracic Oncology. 2nd ed. Philadelphia, PA: Elsevier; 2018.

55. Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R, group TCE. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterology & Hepatology 2018;3:114-24.

56. Perera M, Papa N, Christidis D, McGrath S, Manning T, Roberts M, Bolton D, Lawrentschuk N, Sengupta S. The impact of the global bacille Calmette-Guerin shortage on treatment patterns: population-based data. BJU International 2018;121:169-72.

57. Salgado R, Loi S. Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncology 2018;19:3-5.

58. Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D, Faculty I. Steps forward for cancer precision medicine. Nature Reviews Drug Discovery 2018;17:1-2.

59. Seymour JF, Dohner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer 2017;17:852.

60. Sharp PP, Garnier JM, Hatfaludi T, Xu Z, Segal D, Jarman KE, Jousset H, Garnham A, Feutrill JT, Cuzzupe A, Hall P, Taylor S, Walkley CR, Tyler D, Dawson MA, Czabotar P, Wilks AF, Glaser S, Huang DCS, Burns CJ. Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. ACS Medicinal Chemistry Letters 2017;8:1298-303.

61. Smith K, Winstanley J, Boyle F, O'Reilly A, White M, Antill YC. Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy. Supportive Care in Cancer 2018;26:483-9.

62. Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, Pagliuca A, Cragin L, Jarque I, Garcia-Vidal C, Sorensen S, Vanness DJ, Charbonneau C, Barrueta JA, Peral C, De Salas-Cansado M, Bow EJ. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses 2017;60:79-88.

63. Sonnenblick A, Salgado R, Brohee S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, De Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C. p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. International Journal of Oncology 2018;52:424-32.

64. Spencer A, Harrison S, Zonder J, Badros A, Laubach J, Bergin K, Khot A, Zimmerman T, Chauhan D, Levin N, MacLaren A, Reich SD, Trikha M, Richardson P. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. British Journal of Haematology 2018;180:41-51.

65. Stacker SA, Achen MG. Emerging Roles for VEGF-D in Human Disease. Biomolecules 2018;8.

66. Stafford L, Sinclair M, Turner J, Newman L, Wakefield C, Krishnasamy M, Mann GB, Gilham L, Mason K, Rauch P, Cannell J, Schofield P. Study protocol for Enhancing Parenting In Cancer (EPIC): development and evaluation of a brief psycho-educational intervention to support parents with cancer who have young children. Pilot Feasibility Stud 2017;3:72.

67. Tan L, Alexander M, Officer A, MacManus M, Mileshkin L, Jennens R, Herath D, de Boer R, Fox SB, Ball D, Solomon B. Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. Internal Medicine Journal 2018;48:37-44.

68. Teh BW, Brown C, Joyce T, Worth LJ, Slavin MA, Thursky KA. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Supportive Care in Cancer 2018;26:997-1003.

69. Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, Hicks RJ. Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging 2018;45:323.

70. Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, Hicks RJ. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. European Journal of Nuclear Medicine and Molecular Imaging 2018;45:262-77.

71. Tie J, Semira C, Gibbs P. Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option? Expert Review of Molecular Diagnostics 2018;18:1-3.

72. Trigos AS, Pearson RB, Papenfuss AT, Goode DL. How the evolution of multicellularity set the stage for cancer. British Journal of Cancer 2018;118:145-52.

73. Trubiano JA, Beekmann SE, Worth LJ, Polgreen PM, Thursky KA, Slavin MA, Grayson ML, Phillips EJ. Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. Open Forum Infect Dis 2016;3:ofw153.

74. Trubiano JA, Stone CA, Grayson ML, Urbancic K, Slavin MA, Thursky KA, Phillips EJ. The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration. Journal of Allergy and Clinical Immunology in Practice 2017;5:1532-42.

75. Waibel M, Vervoort SJ, Kong IY, Heinzel S, Ramsbottom KM, Martin BP, Hawkins ED, Johnstone RW. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia. Leukemia 2018;32:237-41.

76. Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, Murphy DG, Nguyen PL, Resnick MJ, Nam RK. Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review. European Urology 2018;73:11-20.

77. Wiede F, Tiganis T. Isolation and Characterization of Mouse Intrahepatic Lymphocytes by Flow Cytometry. Methods in Molecular Biology 2018;1725:301-11.

78. Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Annals of Surgical Oncology 2018;25:356-77.

79. Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, Balch CM, Berman BS, Cochran A, Delman KA, Gorman M, Kirkwood JM, Moncrieff MD, Zager JS, Lyman GH. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 2018;36:399-413.

80. Yannakou CK, Jones K, McBean M, Thompson ER, Ryland GL, Doig K, Markham J, Westerman D, Blombery P. ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach. Blood Cancer Journal 2017;7:656.

81. Yannakou CK, Jones K, Ryland GL, Thompson ER, Reid G, McBean M, Trainer A, Westerman D, Blombery P. Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies. Journal of Clinical Pathology 2018;71:84-7.